Key Performance
More- Earnings Score: 94
- Momentum Score: 17
- True Yield: N/A
- Financial Health Score: 74
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
The global blood glucose monitoring system market is valued at USD 16.8 billion in 2025 and is projected to reach USD 39.4 billion by 2035, growing at a CAGR of 8.9%. Growth is driven by AI-enabled monitoring systems, increasing diabetes prevalence, and rising adoption of home healthcare solutions. Key players include Medtronic, Abbott, Dexcom, and Roche, with recent partnerships like Abbott-Medtronic collaboration to integrate continuous glucose monitoring with automated insulin delivery systems.
07/14/2026, 12:30 AM • GlobeNewswire
Insulet Corporation faces a securities class action lawsuit over defective cannula manufacturing in Omnipod insulin delivery devices. Approximately 7 million Pods were affected by manufacturing defects causing insulin under-delivery. The stock declined from $236 to $146.01 per share following two Medical Device Corrections. Investors who purchased securities between February 21, 2025 and May 26, 2026 may be eligible for compensation, with a lead plaintiff deadline of August 31, 2026.
07/13/2026, 10:00 AM • GlobeNewswire
Rosen Law Firm has filed class action lawsuits on behalf of investors in Insulet Corporation (PODD), GRAIL, Inc. (GRAL), and GeneDx Holdings Corp. (WGS). The lawsuits allege that defendants made false or misleading statements regarding manufacturing controls, product safety compliance, and regulatory risks. Investors who purchased securities during the specified class periods may be eligible for compensation. The lead plaintiff deadline is August 31, 2026.
07/11/2026, 7:11 PM • GlobeNewswire
A securities class action lawsuit has been filed against Insulet Corporation alleging the company made false and misleading statements about its manufacturing controls and procedures. The lawsuit covers investors who purchased Insulet securities between February 21, 2025 and May 26, 2026. Two voluntary medical device corrections were disclosed in March and May 2026 involving manufacturing issues with Omnipod products, resulting in significant stock price declines. The deadline to seek lead plaintiff status is August 31, 2026.
07/11/2026, 8:35 AM • GlobeNewswire
The Schall Law Firm is seeking investors who purchased Insulet Corporation (NASDAQ: PODD) securities between February 21, 2025 and May 26, 2026 to join a class action lawsuit alleging securities fraud. The lawsuit claims Insulet made false and misleading statements regarding defective manufacturing controls, increased safety violation risks, and understated the scope of its March 2026 Medical Device Correction affecting Pod Products.
07/10/2026, 9:51 AM • GlobeNewswire
A class action lawsuit has been filed against Insulet Corporation alleging that the company made materially false and misleading statements regarding its business operations and compliance policies. The complaint specifically claims that Insulet's manufacturing controls and procedures were defective, creating a foreseeable risk that products could violate safety regulations. Investors who purchased Insulet securities between May 21, 2025 and May 26, 2026 are encouraged to join the case, with a lead plaintiff deadline of August 31, 2026.
07/09/2026, 12:00 PM • GlobeNewswire
The Rosen Law Firm is investigating potential securities claims against GoDaddy Inc., Wise Group plc, and Insulet Corporation on behalf of shareholders, alleging these companies issued materially misleading business information. Investors who purchased securities in these companies may be entitled to compensation through class action lawsuits.
07/08/2026, 9:56 PM • GlobeNewswire
Rosen Law Firm has filed a class action lawsuit against Insulet Corporation (PODD) on behalf of investors who purchased securities between February 21, 2025 and May 26, 2026. The lawsuit alleges that Insulet made false and misleading statements regarding defective manufacturing controls and procedures that created a foreseeable risk of safety violations. Investors who wish to serve as lead plaintiff must file by August 31, 2026.
07/08/2026, 9:49 PM • GlobeNewswire
Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Futu Holdings Limited, Hub Group, Inc., and Insulet Corporation. The lawsuits allege materially false statements and/or failure to disclose material facts regarding compliance, financial results, and manufacturing controls respectively. Investors who purchased shares and suffered losses are encouraged to seek legal representation.
07/07/2026, 4:53 PM • GlobeNewswire
A securities class action lawsuit has been filed against Insulet Corporation for allegedly failing to disclose defective manufacturing controls and procedures that created a heightened risk of product safety violations. The lawsuit covers the period from February 21, 2025 to May 26, 2026. Investors have until August 31, 2026 to file as lead plaintiffs.
07/06/2026, 10:49 AM • GlobeNewswire
A shareholder class action lawsuit has been filed against Insulet Corporation (NASDAQ: PODD) alleging that the company made false and misleading statements regarding defective manufacturing controls and procedures that created a foreseeable risk of product safety violations. The lawsuit covers investors who purchased shares between February 21, 2025 and May 26, 2026. The deadline to be appointed lead plaintiff is August 31, 2026.
07/06/2026, 10:49 AM • GlobeNewswire
Rosen Law Firm has filed securities class action lawsuits against Veritone, Insulet Corporation, and Genius Group Limited. The primary case involves Veritone, which allegedly made false statements about its financial performance, including inaccurate revenue recording, misclassification of costs, and deficient internal controls. Investors with losses exceeding $100,000 are encouraged to join the class action before the July 20, 2026 lead plaintiff deadline.
07/05/2026, 7:37 PM • GlobeNewswire
Rosen Law Firm has filed class action lawsuits against Insulet Corporation, Genius Group Limited, and First Solar, Inc. on behalf of investors who purchased securities during specified periods. The lawsuits allege that defendants made false or misleading statements regarding manufacturing controls, product safety, and regulatory compliance. Investors have until August 31, 2026 to move the court to serve as lead plaintiff.
07/05/2026, 6:35 PM • GlobeNewswire
A class action lawsuit has been filed against Insulet Corporation alleging that the company made materially false and misleading statements regarding its business operations and compliance policies. The complaint specifically claims that Insulet's manufacturing controls were defective, creating a foreseeable risk that products would violate safety regulations. The class period covers purchases between May 21, 2025 and May 26, 2026, with a lead plaintiff deadline of August 31, 2026.
07/03/2026, 3:08 PM • GlobeNewswire
FDA Flags High-Risk Recall Of Insulet's Omnipod 5 Pods Over Insulin Delivery Concerns
The FDA has classified Insulet's Omnipod 5 insulin pump recall as its most serious type due to a defect causing potential insulin under-delivery. The flaw involves small tears in internal tubing that can lead to insulin leakage without triggering alarms, risking elevated blood glucose levels and potentially life-threatening diabetic ketoacidosis. The company reported 476 serious injuries with no deaths. Insulet shares fell 10.95% to a new 52-week low of $162.84.
04/29/2026, 2:30 PM • Benzinga
Peers
Statistics
MoreInformation as of 07/13/2026
Company Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.